CC BY-NC-ND 4.0 · Laryngorhinootologie 2019; 98(S 02): S310
DOI: 10.1055/s-0039-1686359

Individualized vibrotactile neurofeedback training and Ginkgo biloba special extract in presbyvertigo – a multicentre, randomized, controlled, single-blind trial

L Decker
1   Unfallkrankenhaus Berlin, Klinik für HNO, Berlin
B Dietmar
1   Unfallkrankenhaus Berlin, Klinik für HNO, Berlin
M Burkart
2   Dr. Wilmar Schwabe GmbH, Karlsruhe
A Ernst
1   Unfallkrankenhaus Berlin, Klinik für HNO, Berlin
› Author Affiliations
Dr. Wilmar Schwabe GmbH


Vestibular rehabilitation using VertiGuard® RT individualized vibrotactile neurofeedback training (IVNT) improves balance in everyday situations and dizziness in patients with chronic vertigo, including presbyvertigo. Ginkgo biloba special-extract EGb 761® facilitates learning, improves dizziness in this patient group and enhances the effect of balance training. Synergistic effects can be expected from the combination of both treatment modalities in this difficult-to-treat population.


Patients age 60 years and older with non-compensated multimodal vertigo for > 3 months, Dizziness Handicap Inventory (DHI) total score > 25 and fall risk > 40% assessed by the geriatric Standard Balance Deficit Tests (gSBDT) were treated with 160 mg EGb 761®/day for 12 weeks including 2 weeks individualized balance training, randomised single-blind to vibrotactile neurofeedback or insensitive sham-feedback using VertiGuard® RT.


120 out of 190 screened patients were enrolled into the trial of whom 109 received both treatments at least once. In the total sample the gSBDT fall risk improved from 56.1% to 50.6%, the DHI total score from 44.1 to 31.1. Cognitive function (Trail Making Test, difference part B – part A) improved from 70.4 s to 56.9 s in parallel, while audiometric hearing threshold remained unchanged. The combination treatment was safe and well tolerated.


With the combination of IVNT and EGb 761®, improvements in the DHI in the total sample were larger, improvements in the gSBDT fall risk comparable to previous observations in this patient group treated with IVNT alone or in combination with cinnarizine/dimenhydrinate. Unblinded study results will be presented.

Publication History

Publication Date:
23 April 2019 (online)

© 2019. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (

Georg Thieme Verlag KG
Stuttgart · New York